Generation Bio Co. reports third quarter net loss of $5.5 million
Generation Bio Co. reported a net loss of $5.5 million for Q3 2025, an improvement from a $15.3 million loss in Q3 2024. The company's cash position decreased to $89.6 million from $185.2 million at the end of 2024. R&D expenses rose to $21.7 million, while general and administrative expenses increased to $12.2 million. Additionally, the company settled litigation with its landlord, resulting in a $25.5 million gain on lease termination.
Generation Bio Co. reported a cash position of $89.6 million as of September 30, 2025, down from $185.2 million at the end of 2024. Research and development expenses for the third quarter were $21.7 million, up from $15.1 million in the same period last year. General and administrative expenses rose to $12.2 million from $9.2 million. The company reported a net loss of $5.5 million, or $0.82 per share, compared to a net loss of $15.3 million, or $2.29 per share, in the third quarter of 2024. In August 2025, Generation Bio settled litigation with its Waltham, MA facility landlord, paying $31.0 million and recording a $25.5 million gain on lease termination. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generation Bio Co. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569452-en) on November 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
